Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation

Leuk Lymphoma. 2022 Sep;63(9):2254-2256. doi: 10.1080/10428194.2022.2064992. Epub 2022 Apr 15.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Costs and Cost Analysis
  • Cytomegalovirus
  • Cytomegalovirus Infections* / diagnosis
  • Cytomegalovirus Infections* / etiology
  • Cytomegalovirus Infections* / therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Treatment Failure

Substances

  • Antiviral Agents